How excluding some benefits from value assessment of new drugs impacts innovation
Year of publication: |
December 2017
|
---|---|
Authors: | Cook, Joseph P. ; Golec, Joseph |
Published in: |
Health economics. - Chichester : Wiley-Blackwell, ISSN 1057-9230, ZDB-ID 1135838-5. - Vol. 26.2017, 12, p. 1813-1825
|
Subject: | biopharmaceuticals | cost-effectiveness | options | Innovation | Arzneimittel | Pharmaceuticals | Pharmaindustrie | Pharmaceutical industry | Pharmakologie | Pharmacology | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis |
-
Pharmacoeconomics : from theory to practice
Arnold, Renée J. G., (2010)
-
Understanding health outcomes and pharmacoeconomics
MacKinnon, George E., (2013)
-
Risk-sharing agreements in pharmaceutical markets
Antoñanzas Villar, Fernando, (2013)
- More ...
-
Real option value and path dependence on oncology innovation
Cook, Joseph P., (2011)
-
Generic utilization rates, real pharmaceutical prices, and research and development expenditures
Cook, Joseph P., (2010)
-
On understand the increase in US patent litigation
Cook, Joseph P., (2007)
- More ...